{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-095925","form_type":"8-K/A","ticker":"VYNE","cik":"0001566044","company_name":"VYNE Therapeutics Inc.","filed_at":"2026-08-13T20:14:54+00:00","discovered_at":"2026-08-13T20:16:00.284804+00:00","generated_at":"2026-08-13T20:16:24.032489+00:00","sec_items":["2.02","9.01","7.01"],"event_type":"m_and_a","sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Yarrow (fka VYNE) closes reverse merger with YB-101 developer; $100M cash, $71M net loss","bullets":["Merger closed July 27, 2026: VYNE issued 2,130,731 shares at 0.7171 exchange ratio; 25.6M pre-funded warrants and 2.0M options converted.","Pre-Merger Yarrow raised $99.85M net via 14,516,188 Series A preferred shares at $6.89/share; cash of $99.99M at Dec 31, 2025.","Net loss of $70.99M from Oct 3, 2025 inception to Dec 31, 2025, including $70M acquired in-process R&D (upfront license fee to GenSci).","Lead asset YB-101 (anti-TSHR antibody for Graves' disease) received FDA IND clearance March 2026; Phase 2a/2b trial expected H1 2026.","Cash of $30M remains after $70M license fee; management says sufficient for 12+ months of operations."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-095925","json":"https://secwatch.observer/filing/0001104659-26-095925.json","markdown":"https://secwatch.observer/filing/0001104659-26-095925.md","text":"https://secwatch.observer/filing/0001104659-26-095925.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1566044/000110465926095925/0001104659-26-095925-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1566044/000110465926095925/tm2622598d1_8ka.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-13T20:16:24.032489+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}